ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 20164688

Triple-negative breast cancer: role of antiangiogenic agents.

Greenberg S and 1 other. Cancer J, 2010. Cited by 54 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Triple-negative breast cancer: role of antiangiogenic agents. Papers, record 20164688. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20164688

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Triple-negative breast cancer: role of antiangiogenic agents.
PubMed
Journal
Cancer J
PubMed
Year
2010
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
54
iCite
Relative citation ratio, by iCite
1.24
iCite
Revised in PubMed
2026-01-28
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Greenberg SSally
2Rugo HSHope S

Source PubMed

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Angiogenesis InhibitorsMajor topic
Breast NeoplasmsMajor topic
Neovascularization, PathologicMajor topic
Female
Humans
Prognosis
Erb-b2 Receptor Tyrosine Kinases
Receptors, Estrogen
Receptors, Progesterone

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by31

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 54 citations.

PMIDTitleJournalYearIn PapersSource
41,476,672The Landscape of Potential Targeted Treatments and Chemotherapy Efficacy Biomarkers for TNBC.Breast Cancer (Dove Med Press)2025https://conductscience.org/library/papers/41476672PubMed
39,668,367Targeting RTKs/nRTKs as promising therapeutic strategies for the treatment of triple-negative breast cancer: evidence from clinical trials.Mil Med Res2024https://conductscience.org/library/papers/39668367PubMed
38,256,245Programmed Death-Ligand (PD-L1), Epidermal Growth Factor (EGF), Relaxin, and Matrix Metalloproteinase-3 (MMP3): Potential Biomarkers of Malignancy in Canine Mammary Neoplasia.Int J Mol Sci2024https://conductscience.org/library/papers/38256245PubMed
33,994,723Molecular Biology in the Breast Clinics-Current status and future perspectives.Indian J Surg Oncol2021https://conductscience.org/library/papers/33994723PubMed
31,186,728Prognostic impact of interleukin-6 and C-reactive protein on patients with breast cancer.Oncol Lett2019https://conductscience.org/library/papers/31186728PubMed
30,071,865A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.Breast Cancer Res2018https://conductscience.org/library/papers/30071865PubMed
29,391,830Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going.Cancer Manag Res2018https://conductscience.org/library/papers/29391830PubMed
29,049,198Expression analysis of E-cad and vascular endothelial growth factor in triple-negative breast cancer patients of different ethnic groups in western China.Medicine (Baltimore)2017https://conductscience.org/library/papers/29049198PubMed
27,579,484
Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis.
PLoS One2016https://conductscience.org/library/papers/27579484PubMed
27,347,130Effects of melatonin on HIF-1α and VEGF expression and on the invasive properties of hepatocarcinoma cells.Oncol Lett2016https://conductscience.org/library/papers/27347130PubMed

1 to 10 of 31

See all 31 cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ERBB22,064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
MTOR2,475PubTator's text mininghttps://conductscience.org/library/genes/2475NCBI Gene
VEGFA7,422PubTator's text mininghttps://conductscience.org/library/genes/7422NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20164688

GET https://conductscience.org/api/papers/v1/20164688/cited_by?page=2

API referenceFor AI assistants